Margarita Majem Tarruella

39PUBLICATIONS
197CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer diagnosisMolecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Oct 27, 2026
Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.

|Jul 28, 2026
Soluble Immune Checkpoints as Prognostic Biomarkers in Small Cell Lung Cancer Patients Treated with Chemotherapy and Anti-PD-L1.

|Mar 17, 2026
Recommendations for the development of an integrated lung cancer care process: an expert consensus report.

Margarita Majem, Patricia Alonso-Fernández, Pilar Garrido López

|Mar 10, 2026
Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.

Belén Sierra-Rodero, Ángeles Gil-González, Marta Molina-Alejandre

|Mar 01, 2026
Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial).

Aida Piedra, Albert Guinart-Cuadra, Sergio Martínez-Recio

|Jan 28, 2026
Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody-drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology.

Margarita Majem, Kevin Molina Mata, Ander Mayor Ibarguren

Pageof 7

Frequent Collaborators

6 joint publications

Manuel Cobo

5 joint publications

Dolores Isla

5 joint publications

Ernest Nadal

5 joint publications

Ivana Sullivan